European Union drug regulators said Wednesday that there was a “potential link” between the AstraZeneca CCP virus vaccine and “very rare” blood clots, but recommended that vaccination be continued. He emphasized that profits outweigh risks.
The European Medicines Agency (EMA) has been vaccinated with medical professionals to continue to recognize the possibility of very rare blood clots combined with low levels of platelets that occur within two weeks of vaccination. It calls people’s attention. ” Said in a statement Wednesday.
The statement continues as follows: “So far, most of the reported cases have occurred in women under the age of 60 within two weeks of vaccination. No specific risk factors have been identified based on currently available evidence. Hmm.”
The Epoch Times contacted AstraZeneca for comment. Pharmaceutical giants and the World Health Organization (WHO) have previously stated that the study does not increase the risk of blood clots from vaccines.
According to an EMA statement, EMA officials reviewed dozens of cases, primarily from Europe and the United Kingdom. There, about 25 million people were vaccinated with the AstraZeneca vaccine.
“Cases of abnormal blood clotting reported after vaccination with the AstraZeneca vaccine should be listed as possible side effects of the vaccine,” said Emer Cooke, the secretary general of the agency. Reporter.. “The risk of death from COVID is much greater than the risk of death from these side effects,” Cook said.
Last month, more than 12 European countries, including France, Germany, Italy and Spain, stopped using the AstraZeneca vaccine after reports of blood clots and the deaths of several people who were shot. Most countries have resumed vaccination, but some have suspended elderly vaccinations.
Marco Cavaleri, chair of the EMA vaccine evaluation team, said the possible causes of blood clots are not yet fully understood.
“In my opinion, I can say that now. It’s clear that it’s related to vaccines, but I’m still not sure what’s causing this reaction,” he said in the Italian media. Told to.
On Tuesday, AstraZeneca and the University of Oxford, which developed the vaccine, suspended research on child shots while UK regulators were assessing the association between adult shots and rare blood clots.
Officials in the Castile and Leon region of Spain have also stopped using the vaccine. Local health director Veronica Casado reported on Wednesday that the AP urged temporary suspension of vaccines that the “principle of prudence” still supports her as effective and necessary.
“If you have individuals in a certain age group who may actually be at high risk (of coagulation), you need to adjust their use,” Cassadó said. “We are not questioning AstraZeneca. We need all possible vaccines to reach our goal of 70% of the adult population.”
The Associated Press contributed to this report.